A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).

Start Date01 Dec 2026

Sponsor / Collaborator

Eli Lilly & Co.

NCT07729332

/ Not yet recruitingPhase 4IIT

Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1-based Therapy Discontinuation

This study will compare the effect of orforglipron and phentermine on weight maintenance.

Start Date01 Nov 2026

Sponsor / Collaborator

The Massachusetts General Hospital

NCT07739537

/ Not yet recruitingPhase 4IIT

Polygenic Assessment and Testing of Heterogeneity and Subtypes in Type 2 Diabetes (PATHS-T2D): A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

This research study aims to learn about how the body responds to food through different genetic pathways and how these responses may change during a short course of orforglipron. Orforglipron is an oral glucagon-like peptide-1 (GLP-1) receptor agonist that was approved by the U.S. Food and Drug Administration (FDA) on April 1, 2026, for long-term weight management. In longer studies, it has helped people lose weight and improve blood sugar, blood pressure, and cholesterol. By taking part, participants will receive detailed metabolic testing and may receive study results with additional information about their blood sugar and metabolic health.

Start Date01 Oct 2026

Sponsor / Collaborator

The Massachusetts General Hospital

100 Clinical Results associated with Orforglipron

100 Translational Medicine associated with Orforglipron

100 Patents (Medical) associated with Orforglipron

Literatures (Medical) associated with Orforglipron

01 Nov 2026·BIOCHEMICAL PHARMACOLOGY

Orforglipron alleviates aortic aneurysm and dissection via inhibiting WNT5A noncanonical signaling

Article

Author: Zhang, Junhao ; Chen, Xing ; Wang, Dongjin ; Deng, Yong ; Qian, Jintao ; Wang, Jiahui ; Guo, Zhiyi ; Xu, Zhiwei ; Kong, Chuiyu ; Yu, Lichun

Aortic aneurysm and dissection (AAD) are life-threatening vascular diseases for which effective pharmacological therapies remain limited. Smooth muscle cell phenotypic switching plays a central role in AAD development and progression. Orforglipron, a novel orally active non-peptide glucagon-like peptide-1 receptor agonist, has shown potential cardiovascular benefits; however, its role in AAD remains unclear. In this study, male B6 humanized GLP-1R mice were treated with orforglipron by oral gavage for 28 consecutive days and subjected to beta-aminopropionitrile combined with angiotensin II infusion to induce AAD. Orforglipron treatment protected mice from smooth muscle cell phenotypic switching, medial degeneration, and AAD formation. RNA sequencing of human aortic smooth muscle cells identified Wnt5a as a key downstream target regulated by orforglipron. Mechanistically, orforglipron inhibited ERK phosphorylation, reduced EGR1 expression, and thereby suppressed EGR1-mediated Wnt5a transcription. Conditional deletion of Wnt5a in smooth muscle cells significantly attenuated AAD progression, whereas activation of JNK signaling aggravated vascular remodeling and AAD development. These findings demonstrate that orforglipron attenuates smooth muscle cell phenotypic switching and AAD progression by modulating the ERK/EGR1/Wnt5a/JNK signaling axis, supporting orforglipron as a promising therapeutic candidate for aortic diseases.

01 Sep 2026·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Variant-specific pharmacophoric shifts in glucagon-like peptide-1 receptor–orforglipron complexes revealed by Boltz-2 co-folding and membrane molecular dynamics

Article

Author: Rajan, Ramya ; Al-Mulla, Fahd ; Mohammad, Anwar ; Dashti, Mohammed ; Malik, M D Zubbair

BACKGROUND:

Orforglipron (ORF), the first orally bioavailable non-peptide glucagon-like peptide-1 receptor (GLP-1R) agonist to complete Phase 3 clinical trials, binds a distinct extracellular vestibule pocket not engaged by peptide GLP-1RAs. How commonly GLP-1R single-nucleotide polymorphisms alter this unique binding mode at the molecular level remains uncharacterized.

METHODS:

We employed an integrative computational framework that combines Boltz-2 deep learning co-folding for variant complex generation, 500 ns all-atom molecular dynamics simulations in a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipid bilayer, MM/GBSA binding free-energy decomposition, and protein ligand hydrogen-bond occupancy analysis. Wild-type (WT) GLP-1R and four clinically annotated variants L260F^3.53b (TM3), G168S (stalk), R131Q (ECD), and A316T^5.46 (TM5) were characterized.

RESULTS:

All variants exhibited enhanced MM/GBSA binding (24-35% vs WT) despite conformational destabilization, as evidenced by elevated RMSD, altered free energy landscapes, and reorganized H-bond networks. H-bond occupancy trajectory analysis identified Lys197^2.67 as the canonical pharmacophoric anchor in WT (79.8%), preserved in L260F (57.1%) and A316T (63.9%). However, Lys197^2.67 was absent in G168S and R131Q, which substitute Tyr205^2.75/Gln221 and Tyr202, respectively. G168S exhibited the strongest binding (-117.18 kcal/mol) through compensatory contacts, while displaying a diffuse free-energy landscape and conformational disorder. A316T exhibited bistable dynamics related to Y242^3.45-T316^5.46H-bond-mediated constitutive activation, while preserving canonical engagement.

CONCLUSIONS:

Binding energies and contact analysis describe variant-dependent ORF engagement. Binding enhancement alone is insufficient to characterize pharmacophoric quality. Lys197^2.67 occupancy differentiates variants with canonical binding from those substituting it, offering a structure-based framework for pharmacogenomic associations. The loss of Lys197^2.67 in G168S offers a testable structural hypothesis for the diminished glycemic response observed in carriers, which requires functional validation.

04 Aug 2026·JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes

Article

Author: Denning, Max ; Ludwig, Lisa ; Fernández Landó, Laura ; Ibriga, Hilda ; Kiyosue, Arihiro ; Rha, Hyungmin ; Tobian, Janet ; Wu, Wen-Shuo ; Giorgino, Francesco ; D’Souza, Sherwin

Importance:

The effects of orforglipron, an oral, nonpeptide glucagon-like peptide 1 receptor agonist, added to insulin glargine for treatment of type 2 diabetes have not been described.

Objective:

To assess efficacy and safety of orforglipron added to titrated insulin glargine in adults with type 2 diabetes and inadequate glycemic control.

Design, Setting, and Participants:

Randomized, double-blind, phase 3 study conducted at 72 sites across the US, Brazil, China, Japan, and Romania between November 10, 2023, and September 15, 2025, in adults with type 2 diabetes taking insulin glargine with or without metformin and/or sodium-glucose cotransporter 2 inhibitors over 40 weeks.

Interventions:

Participants were randomized (1:1:1:1) to receive once-daily 3-mg (n = 137), 12-mg (n = 132), or 36-mg (n = 136) dosages of orforglipron or placebo (n = 141), in addition to titrated insulin glargine.

Main Outcomes and Measures:

The primary outcome was mean hemoglobin A 1c (HbA 1c ) change from baseline to week 40 (for the 12-mg once daily and 36-mg once daily dosages of orforglipron). Key secondary outcomes were mean HbA 1c change from baseline (for the 3-mg once daily dosage of orforglipron), proportion of participants achieving HbA 1c targets of lower than 7.0% and 6.5% or lower, and mean body weight change and percentage change from baseline to week 40.

Results:

Among 546 randomized participants (median age, 61.0 [IQR, 26-95] years; 52.9% male; median duration of type 2 diabetes, 14.6 [IQR, 0.1-40.7] years; mean HbA 1c , 8.50% [SD, 0.95%]; mean body mass index, 30.8 [SD, 6.1]), 507 (92.9%) completed the trial. At week 40, the mean changes from baseline in HbA 1c were −1.58%, −1.88%, and −1.82% with orforglipron, 3 mg, 12 mg, and 36 mg once daily, respectively, vs −0.79% with placebo. Each dosage of orforglipron was superior to placebo (estimated treatment differences: 3 mg once daily, −0.78% [95% CI, −1.02% to −0.55%]; 12 mg once daily, −1.08% [95% CI, −1.33% to −0.83%]; 36 mg once daily, −1.03% [95% CI, −1.28% to −0.77%]; P &lt; .001 for all). All key secondary outcomes demonstrated statistically significant differences in favor of orforglipron compared with placebo. Mean percentage body weight change from baseline was −2.6%, −4.8%, and −5.4% with orforglipron, 3 mg once daily, 12 mg once daily, and 36 mg once daily, respectively, vs 0.2% with placebo. The most frequent adverse events with orforglipron were gastrointestinal (mild to moderate). Orforglipron did not increase the risk of clinically significant hypoglycemia vs placebo.

Conclusions and Relevance:

In participants with type 2 diabetes inadequately controlled by insulin glargine, addition of oral orforglipron significantly improved glycemic control and body weight, without increasing hypoglycemia risk, compared with placebo.

Trial Registration:

ClinicalTrials.gov Identifier: NCT06109311

409

News (Medical) associated with Orforglipron

03 Sep 2026

·allsci.com

Hengrui files Kailera-partnered oral GLP-1 for China approval in obesity and diabetes

China's drug regulator has accepted a marketing authorization application for HRS-7535 tablets, an oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist developed by Jiangsu Hengrui Pharmaceutical Co. (HKEX: 01276), for long-term weight management in adults with obesity or overweight. The filing, submitted through Hengrui's subsidiary Shandong Shengdi Pharmaceutical, covers adults with a body mass index (BMI) of 28 kg/m² or above, or 24 kg/m² or above accompanied by at least one weight-related comorbidity. The submission follows positive topline results from the Phase III HARBOR-1 trial, in which 556 adults across 50 centers in China received once-daily HRS-7535 at 120 mg or 180 mg, or placebo. All dose groups met the primary and key secondary endpoints at 44 weeks. The 180 mg group achieved mean weight loss of 10.9% at week 44, extending to 11.1% at week 50 with continued treatment. Improvements in cardiometabolic indicators were also reported. The company said safety and tolerability were consistent with other oral GLP-1 therapies, with no new safety signals and a favorable hepatic safety profile — a feature the filing highlights given the high co-prevalence of fatty liver disease in the target Chinese patient population. One day earlier, on September 2, Hengrui disclosed that the National Medical Products Administration (NMPA) had also accepted a separate marketing application for HRS-7535 in type 2 diabetes, supported by the Phase III OUTSTAND-1 and OUTSTAND-2 trials. Across both studies, HRS-7535 reduced HbA1c by 1.40% to 1.68% across dose groups, with the 90 mg dose demonstrating superiority to dapagliflozin in OUTSTAND-2. HRS-7535 acts as a non-peptide oral agonist of the GLP-1 receptor which can be formulated as a conventional oral tablet. In terms of the Chinese market conditions for obesity, both leading injectables, semaglutide (Wegovy) and tirzepatide (Mounjaro), received NMPA approval in 2024. No oral small-molecule GLP-1R agonist is currently marketed in China. Globally, Eli Lilly’s orforglipron (Foundayo) received US FDA approval in April 2026, validating the oral small-molecule GLP-1 class commercially. HRS-7535 would bring that approach into a Chinese obesity market currently dominated by injectable incretins. Kailera Therapeutics (Nasdaq: KLRA), which licensed HRS-7535 outside Greater China in 2024 under the name KAI-7535, is evaluating the drug in a global Phase II obesity study in the US and Australia, with data expected in 2027. The trial is testing a broader dose range and slower titration schedule than HARBOR-1, with tolerability likely to be an important focus after gastrointestinal adverse events including nausea and vomiting were common in the China study. Spot something wrong? Report an issue with this article

Phase 3Clinical ResultDrug ApprovalPhase 2

28 Aug 2026

·healthcare-digital.com

Study: Eli Lilly’s Zepbound Linked To Lower Healthcare Costs

Eli Lilly’s GLP-1 portfolio includes Type 2 diabetes medications Mounjaro and Trulicity, as well as oral GLP-1 pill Foundayo designed to tackle weight management and type 2 diabetes. Credit: Pexels Eli Lilly’s Zepbound has been linked with lower health costs, with CEO David Ricks saying the results show the value of investing in obesity treatment A study of nearly 16,000 adults over 55 with obesity in the US found that individuals using Eli Lilly 's Zepbound weight management drug had lower healthcare costs relative to untreated adults not using a GLP-1 treatment. Zepbound was already the most-prescribed branded weight management medicine in 2025, with Eli Lilly reporting US$4.2bn in Zepbound revenue in Q4 2025 alone. Fewer hospital and emergency department admissions for Zepbound users drove the lower healthcare costs. Alongside Zepbound, Eli Lilly’s GLP-1 portfolio includes Type 2 diabetes medications Mounjaro and Trulicity, as well as oral GLP-1 pill Foundayo designed to tackle weight management and type 2 diabetes. David A. Ricks, chair and CEO of Eli Lilly and Company. Credit: Eli Lilly Discussing the results on LinkedIn, David Ricks, CEO of Eli Lilly, writes, “Real-world evidence demonstrates obesity coverage is an investment that pays off for patients and healthcare systems. As Medicare, states and employers consider expanding access to obesity treatment, this report provides valuable evidence to support those decisions.” “ Real-world evidence demonstrates obesity coverage is an investment that pays off for patients and healthcare systems. ” David Ricks CEO of Eli Lilly Real-world evidence The results, published in the Diabetes, Obesity and Metabolism medical journal, offer a range of real-world results. The study covered a high-risk demographic: more than 40% of participants had at least four weight-related comorbidities, while 21% also had an emergency department visit during the baseline period. A key finding from the analysis was that Zepbound-associated healthcare savings increased the longer patients remained on treatment. Zepbound Study: Key Numbers 40% of participants had four or more weight-related comorbidities 21% had an emergency department visit at baseline 15% lower healthcare costs at six months Up to US$607 monthly savings at 12 months Savings exceeded Medicare’s US$195 monthly treatment cost after 12 months Changes over time At six months, healthcare costs were up to 15% lower, representing savings of as much as US$181 per patient per month compared with those not receiving Zepbound. By 12 months, the gap had widened substantially, with estimated savings reaching US$607 per patient per month – equivalent to healthcare costs up to 38% lower. Lower rates of hospital admissions and emergency department visits across every follow-up period accompanied the reduction. Meanwhile, Zepbound-treated patients recorded numerically higher rates of routine outpatient and office visits, suggesting greater engagement with regular care rather than acute services. Importantly, the estimated savings began to offset the US$195 monthly treatment cost of Zepbound through the Medicare GLP-1 Bridge at six months. From 12 months onwards, estimated healthcare savings exceeded the cost of treatment, pointing to the potential for sustained Zepbound use in an older population to generate net healthcare savings over time. Ilya Yuffa, Executive Vice President and President of Eli Lilly USA and Global Customer Capabilities. Credit: LinkedIn "This compelling real-world evidence highlights the impact that treating obesity with Zepbound can have on older patients and the healthcare system," says Ilya Yuffa, Executive Vice President and President of Eli Lilly USA and Global Customer Capabilities. "This analysis shows treatment costs can be lowered, and in some cases more than covered, by savings elsewhere in care – including for payers and in Medicare. As coverage expands across Medicare, states and employers, these data offer evidence on the cost implications of long-term obesity treatment and should help shape decisions." Medicare’s GLP-1 Bridge programme The study comes at a pivotal moment. The Medicare GLP-1 Bridge began on 1 July 2026, a temporary US government programme designed to give eligible Medicare beneficiaries access to certain GLP-1 medicines specifically for weight management. It is run by the Centers for Medicare & Medicaid Services (CMS) and will run until 31 December 2027. It comes amid a period of declining coverage of GLP-1 treatments among US employers., A Business Group on Health survey published on 25 August 2026 showed fewer employers are covering GLP-1s to treat obesity, with coverage falling from 72% in 2025 to 60% in 2026. Against this backdrop, evidence that Zepbound may reduce wider healthcare costs within 12 months could strengthen the case for sustained access to GLP-1 treatments. Eli Lilly – key partners NVIDIA CEO : Jensen Huang | HQ : Santa Clara, California NVIDIA is a US technology company specialising in accelerated computing and artificial intelligence. Lilly and NVIDIA are investing up to US$1bn over five years in an AI co-innovation lab focused on drug discovery, robotics and physical AI. Insilico Medicine CEO : Alex Zhavoronkov | HQ : Hong Kong Insilico Medicine is an AI-powered drug discovery company. Lilly expanded its partnership with Insilico in 2026 through a deal worth up to US$2.75bn, combining Insilico’s AI platforms with Lilly’s drug development expertise to advance novel oral medicines. CVS Health CEO : David Joyner | HQ : Woonsocket, Rhode Island Eli Lilly is partnering with CVS to expand access to Zepbound and Foundayo, with eligible patients able to view transparent pricing through the CVS Health app and access same-day pickup and pharmacist support at CVS pharmacies. Company portals CVS Health Eli Lilly Insilico Medicine NVIDIA Executives David Ricks Chair and CEO

25 Aug 2026

·www.biospace.com

Lilly takes oral obesity race abroad with UK launch of Foundayo

iStock, cihanterlan Eli Lilly’s best play for Foundayo is to bring it overseas, a more price-sensitive market where the pharma can more readily outcompete Novo Nordisk “given the high margins of a small-molecule therapy,” Truist analyst Srikripa Devarakonda told BioSpace . Eli Lilly has launched its weight loss pill Foundayo in the U.K., a move that analysts told BioSpace will allow the pharma to better compete in the oral obesity market against Danish rival Novo Nordisk. The drug will initially be only available through private prescriptions, though Lilly is currently working with the National Institute for Health and Care Excellence (NICE), according to British news outlet The Guardian . The NICE is an executive body that helps determine which medicines are carried by England’s public health service. BioSpace has reached out to Lilly for more details regarding the launch. The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved Foundayo earlier this month, allowing its use in adults with obesity or who are overweight and who have at least one weight-related comorbidity. The drug is also indicated for type 2 diabetes. In the U.S., Foundayo was approved in April —a decision that kicked off the next stage of the obesity rivalry between Lilly and Novo, this time in the oral arena. Obesity Deep dive: The oral obesity wars BioSpace examines how the FDA approval of Eli Lilly’s oral obesity drug Foundayo has ignited a key race with Novo Nordisk. May 18, 2026 · 3 min read · Heather McKenzie Read more Now, that face-off has come to the U.K., where Novo has a few months head start. The MHRA cleared the Danish pharma’s Wegovy pill in June, marking the first oral weight loss drug to cross the regulatory finish line in the country. Still, the U.K.—and the wider international market—is Lilly’s for the taking, Srikripa Devarakonda, vice president of Biotechnology Equity Research at Truist Securities, told BioSpace earlier this month. Outside of the U.S. (OUS), “we are more bullish on the prospects for Foundayo,” she said. Lilly’s advantage, Devarakonda explained, is the relative ease of manufacturing Foundayo, a small-molecule drug, versus oral Wegovy’s peptide profile, opening up the possibility of better margins. “We think that OUS the markets are more price-sensitive and that Lilly will be able to better compete with oral Wegovy on price points given the high margins of a small-molecule therapy in order to secure favorable volume growth,” she said. With a few months’ head start, Novo has taken an early lead over Lilly in the oral obesity race, reaching over 3,000 patients in its first week following the January launch of its Wegovy pill and bringing in DKK 3.22 billion ($496 million) in the second quarter. Foundayo, meanwhile, hit $98 million in Q2, its first quarter on the market. Obesity Novo takes first round of oral obesity duel. Can it stay ahead of Lilly? Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long. August 19, 2026 · 7 min read · Tristan Manalac Read more

Drug Approval

100 Deals associated with Orforglipron

External Link

KEGG	Wiki	ATC	Drug Bank
D12536	-	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United Kingdom	Eli Lilly & Co.	10 Aug 2026
Obesity	United States	Eli Lilly & Co.	01 Apr 2026
Overweight	United States	Eli Lilly & Co.	01 Apr 2026

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus	NDA/BLA	Canada	Eli Lilly Canada, Inc.	01 Jan 2026
Obesity, Abdominal	Phase 3	United States	Eli Lilly & Co.	01 Sep 2026
Obesity, Abdominal	Phase 3	China	Eli Lilly & Co.	01 Sep 2026
Obesity, Abdominal	Phase 3	Japan	Eli Lilly & Co.	01 Sep 2026
Obesity, Abdominal	Phase 3	Argentina	Eli Lilly & Co.	01 Sep 2026
Obesity, Abdominal	Phase 3	Czechia	Eli Lilly & Co.	01 Sep 2026
Obesity, Abdominal	Phase 3	Germany	Eli Lilly & Co.	01 Sep 2026
Obesity, Abdominal	Phase 3	India	Eli Lilly & Co.	01 Sep 2026
Obesity, Abdominal	Phase 3	Mexico	Eli Lilly & Co.	01 Sep 2026
Obesity, Abdominal	Phase 3	South Korea	Eli Lilly & Co.	01 Sep 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05872620 (ATTAIN-2, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Obesity	1,613	Placebo (Placebo)	krjqcwucfp(vsqdoadssw) = coiqqifasu rnnhmmqjfv (frrccoijgs, 0.215) View more	-	04 Sep 2026
				Orforglipron (6 mg Orforglipron QD)	krjqcwucfp(vsqdoadssw) = wgkonqxieb rnnhmmqjfv (frrccoijgs, 0.356) View more
NCT05869903 (ATTAIN-1, CTgov)	Phase 3	Obesity	3,127	Placebo (Placebo)	kgnuhhokcc(mhrewmyadw) = tzsfmrvzkm tlflfhhlmn (oogbjakadc, 0.247) View more	-	14 Aug 2026
				Orforglipron (6 mg Orforglipron)	kgnuhhokcc(mhrewmyadw) = rcpfnkjmbt tlflfhhlmn (oogbjakadc, 0.302) View more
NCT05931380 (ATTAIN-J, CTgov)	Phase 3	Obesity	238	Placebo (Placebo QD)	howeookvnr(qtujqnmygr) = vxyemhuhuz nhbzkpmmqz (huogutramb, 0.732) View more	-	20 Jul 2026
				Orforglipron (6 mg Orforglipron QD)	howeookvnr(qtujqnmygr) = njbdqcufdq nhbzkpmmqz (huogutramb, 0.866) View more
NCT06023095 (CTgov)	Phase 1	Obesity	24	LY3502970 (LY3502970 (Cohort 1))	lvbocultsj = dgeqmaapni jnypjajxbm (lnwvzdpppq, arlzzupkaw - mdklcertej) View more	-	17 Jul 2026
				LY3502970 (LY3502970 (Cohort 2))	lvbocultsj = vwzmzpchiv jnypjajxbm (lnwvzdpppq, lpdupucdvq - htynijwqng) View more
NCT06370728 (CTgov)	Phase 1	-	30	Orforglipron+Carbamazepine	teehrgrzse(fcdssmeeyr) = bdovjareqt zfnkcdbyfw (hejriqnfsy, 26.6) View more	-	17 Jul 2026
NCT06192108 (ACHIEVE-2, Pubmed \| Lancet)	Phase 3	Diabetes Mellitus, Type 2	962	Orforglipron 3 mg	ptcqwzjdec(lfbqfwarcr) = ikhsmjbxmj xyxjlsczcv (vhsebafkwk ) View more	Positive	01 Jul 2026
				Orforglipron 12 mg	ptcqwzjdec(lfbqfwarcr) = ugcojxmfvu xyxjlsczcv (vhsebafkwk ) View more
NCT06010004 (ACHIEVE-J, CTgov)	Phase 3	Diabetes Mellitus, Type 2	401	Orforglipron (3 mg Orforglipron)	oomrdzkeac = szurefoajh gikxptabaw (glsddgqqzx, nkomhbshyj - kzqxenyrxu) View more	-	30 Jun 2026
				Orforglipron (12 mg Orforglipron)	oomrdzkeac = jdhqkwsiij gikxptabaw (glsddgqqzx, kcfnzbdacc - hhwwtsxjjr) View more
NCT06023095 (ADA2026)	Phase 1	Overweight \| Obesity	24	Orforglipron	zonclxowbv(llnxnkjvpo) = gbkxwqzaro vnvgodpymw (vtrybwnaez ) View more	Positive	20 Jun 2026
NCT06192108 (ACHIEVE-2, ADA2026)	Phase 3	Diabetes Mellitus, Type 2	962	Orforglipron 3 mg	xtwmcepseu(pudihozgwm) = Treatment discontinuations due to GI AE were 5.8-8.3% with OFG and 0.4% with DAPA. pyimlnsapz (cvkrholoas ) View more	Positive	20 Jun 2026
				Orforglipron 36 mg
NCT05936138 (CTgov)	Phase 1	Renal Insufficiency \| Kidney Failure, Chronic	24	LY3502970 (LY3502970 (Normal Renal Function))	hvwhrngctk(jztvnmmsyo) = fzovahxpla ckbadhrikk (oarkhgbfgw, 32.1) View more	-	09 Jun 2026
				LY3502970 (LY3502970 (Severe Renal Impairment))	hvwhrngctk(jztvnmmsyo) = ekozjyfacj ckbadhrikk (oarkhgbfgw, 48.6) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis